How Is Eli Lilly's Revenue Looking for 2027?
Analysts expect Eli Lilly's 2027 revenue to be about $102 billion on the Yahoo Finance consensus (a range of $93.9 billion to $110.5 billion), roughly 15% above the 2026 consensus of $88.7 billion and about 19% above the middle of Lilly's own 2026 guidance of $85 billion to $87 billion. Other sources are lower, near $98 billion, so treat it as a range. Lilly has not given 2027 guidance. The growth rests on Mounjaro and Zepbound volume, new drugs and international launches, while realised US prices are falling. This is analysis, not a recommendation.
What do analysts expect for Lilly's 2027 revenue?
| Source | 2026 revenue | 2027 revenue | Analysts |
|---|---|---|---|
| Yahoo Finance (consensus, October 2026) | $88.68 billion (range $83.4 to $91.6 billion) | $102.11 billion (range $93.9 to $110.5 billion) | 29 for 2026, 27 for 2027 |
| StockAnalysis (S&P Global and TipRanks, October 21) | $88.68 billion | $102.11 billion | 29 |
| WallStreetZen | Inconsistent on the page | $97.66 billion (range $85.4 to $108.8 billion) | 33 |
| Lilly's own 2026 guidance | $85 to $87 billion, raised twice | None given | n/a |
Lilly's 2025 revenue, the midpoint of its 2026 guidance and the analyst consensus for 2026 and 2027, from Yahoo Finance and Lilly's reports as quoted by 24/7 Wall St. in October 2026.
The 2026 consensus sits above the top of Lilly's guidance, which fits a company that has raised guidance twice. The 2027 consensus implies about 15% growth, against about 36% in 2026 and about 45% in 2025, so growth is expected to slow but stay large. Earnings per share are expected to rise from $34.59 to $47.22.
What will drive Lilly's revenue in 2027?
- Mounjaro and Zepbound: in the second quarter they brought in $9.94 billion (up 91%) and $4.93 billion (up 46%), about $14.9 billion together, and volume grew about 60%.
- International: Mounjaro's international revenue grew 172% after China added it to its national reimbursement list.
- New products: Lilly's oral GLP-1 pill is launching, with prescribers growing from about 8,000 to 36,000 in the quarter, and retatrutide is targeted for a US filing in the first quarter of 2027, so it would add little to 2027 sales.
- Medicare: a Medicare programme covering these drugs at $50 a month widens access, at a lower price per patient.
- Capacity: Lilly has announced ten US manufacturing sites since 2020, including a new Houston plant.
What could hold revenue back?
| Headwind | What is known |
|---|---|
| Falling prices | Realised US prices fell about 9% to 13% in the second quarter depending on the source, which management said is built into its guidance |
| Competitor price cuts | Novo plans to cut the Wegovy list price by about 50% from January 1, 2027 |
| Concentration | Two drugs were about $14.9 billion of $22.97 billion of second-quarter revenue |
| Clinical and regulatory risk | Retatrutide's filing timeline and a dispute over how the drug is classified could shift its path |
| Estimate drift | Consensus 2026 EPS fell from $36.91 to $34.59 in 30 days, and 2027 from $47.54 to $47.22 |
See why Eli Lilly is valued so much higher than Novo Nordisk for how the two companies' growth and pricing compare.
What does the price assume?
From this site's weekly data, Lilly closed at $1273.46 on October 23, 2026, a market value of about $1.21 trillion, at 45.4 times trailing earnings and 26.3 times forward earnings. On the consensus 2027 EPS of $47.22 the price is about 27 times 2027 earnings.
Analysts' average price target was $1,332 on StockAnalysis (31 analysts, range $930 to $1,600), about 5% above the price, and 20 of 31 rate it Strong Buy. This site's reverse DCF, shown on the Lilly stock page, says the price needs free cash flow per share to grow faster than 40% a year before fading, which is far above what the consensus revenue growth implies. See what growth does a share price imply for how to read that. A 2027 revenue miss of even a few percent against $102 billion would test a price that already assumes a great deal.
When will we know more?
Lilly has not given 2027 guidance, and the sources did not give a date for it or for the next quarterly report. The third-quarter report will show whether growth near 48% holds and whether guidance rises again. Each report moves the 2027 estimates, which have already shifted in the past month.
Sources
- Yahoo Finance: Eli Lilly analyst estimates (October 2026): revenue and EPS consensus
- StockAnalysis: Eli Lilly forecast (updated October 21, 2026): estimates and price targets
- WallStreetZen: Eli Lilly forecast: alternative consensus (some figures inconsistent on the page)
- 24/7 Wall St. via Yahoo Finance (August 6, 2026; October 13 and 19, 2026): second-quarter results and guidance
- Eli Lilly on this site: price and ratios, October 23, 2026
Consensus figures differ between providers and change often, and some pages show no data date. This is educational content, not investment advice.
Eli Lilly revenue FAQ
What is Eli Lilly's 2027 revenue forecast?
Analysts average about $102 billion on Yahoo Finance and StockAnalysis, with a range of $93.9 billion to $110.5 billion, and about $98 billion on WallStreetZen. Lilly has not given its own 2027 guidance.
How fast will Lilly's revenue grow in 2027?
About 15% above the 2026 consensus of $88.7 billion, according to the Yahoo Finance average, a slowdown from growth near 48% in the second quarter of 2026.
What is Lilly's 2026 revenue guidance?
$85 billion to $87 billion, raised twice, against an analyst consensus of about $88.7 billion.
What could slow Lilly's growth?
Falling realised prices, Novo's planned 2027 price cut, reliance on two drugs, and clinical or regulatory delays for new products such as retatrutide.
Is Eli Lilly stock priced for this growth?
It trades at about 27 times consensus 2027 earnings, and this site's reverse DCF says the price assumes free cash flow growth above 40% a year before fading.